Prognostic significance of oxygen saturation/fraction of inspired oxygen 3 days after initiation of tocilizumab treatment in patients with COVID-19.

Background: Tocilizumab is effective in treating severe coronavirus disease 2019 (COVID-19). However, the specific time point it acts as a valid indicator of treatment efficacy remains unclear. This study aimed to determine the optimal day for assessing the prognostic value of the oxygen saturation/fraction of inspired oxygen (SpO/FiO) and ratio of respiratory rate-oxygenation (ROX) index in patients receiving tocilizumab for COVID-19.

Idiopathic Central Alveolar Hypoventilation wherein Sleep Disordered Breathing Was Considered Well-controlled by the Continuous Positive Airway Pressure Tracking System but Not Controlled by Polysomnography.

A 54-year-old man whose awake percutaneous arterial oxygen saturation (SpO) was 94% was diagnosed with obstructive sleep apnea by polysomnography (PSG). His apnea-hypopnea index (AHI) was 138.8 (AI: 4.

Platypnoea-orthodeoxia syndrome affects nocturnal oxygen desaturation: A case report.

A woman in her late 20s who had received an implantable cardioverter defibrillator in childhood for ventricular arrhythmia was diagnosed with severe obstructive sleep apnoea (apnoea-hypopnoea index, 77.1/h), and she began continuous positive airway pressure treatment. Before initiating this treatment, she had moderate hypoxaemia of unknown cause.